Sandoz is a major global generic pharmaceutical company that has been involved with Yupelri (revefenacin) through its acquisition of a portfolio of respiratory assets from Mylan in 2020 [1]. Yupelri is an inhaled long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1][2].
How does Sandoz's role in Yupelri differ from the original developer?
As a generic manufacturer, Sandoz's primary involvement with Yupelri has been through its acquisition of rights and the potential for developing and marketing generic versions of the drug once patent protections expire. The original development and approval of Yupelri were by Theravance Biopharma and later marketed by Mylan, now part of Viatris [3][4]. Sandoz's strategy typically involves bringing more affordable generic alternatives to market after exclusivity periods end [1].
What is the mechanism of action for Yupelri?
Yupelri works by blocking the action of acetylcholine on muscarinic receptors in the airways. This blockade leads to bronchodilation, relaxing the smooth muscles in the lungs and widening the airways, which helps to improve airflow in COPD patients [2].
When does patent exclusivity for Yupelri expire?
Information regarding the specific patent expiry dates for Yupelri is available through specialized drug patent databases. For instance, DrugPatentWatch.com tracks patent statuses and expiration dates for pharmaceuticals, which would indicate when generic competition might become possible [5].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri include nasopharyngitis, upper respiratory tract infection, and headache [2]. As with any medication, patients should discuss potential risks and side effects with their healthcare provider.
How does Yupelri compare to other COPD treatments?
Yupelri is a LAMA, a class of drugs that are a cornerstone of COPD maintenance therapy. It provides 24-hour bronchodilation. Other COPD treatments may include short-acting bronchodilators, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or combinations of these [6]. The choice of treatment depends on the severity of the COPD, the patient's symptoms, and their individual response to medication.
What is the pricing and availability of Yupelri?
Pricing for branded medications like Yupelri can vary significantly based on insurance coverage, pharmacy, and location. As a branded drug, it is generally more expensive than generic alternatives. Information on pricing and patient assistance programs may be available through the drug's manufacturer or distributor. Generic versions, once available, are expected to be more affordable [5].
Who are the competitors in the LAMA market for COPD?
The LAMA market for COPD includes other drugs such as tiotropium (Spiriva) and umeclidinium (Incruse Ellipta). Combined therapies, such as LAMA/LABA or LAMA/LABA/ICS, are also widely used and represent significant competition [6]. Sandoz's potential generic entry would add to the competitive landscape by offering a lower-cost alternative.
What is the clinical trial data supporting Yupelri's efficacy?
Clinical trials have demonstrated that Yupelri significantly improves lung function, as measured by forced expiratory volume in one second (FEV1), compared to placebo in patients with COPD. These studies evaluated its efficacy over a 24-week treatment period [2].
Sources:
[1] https://www.drugpatentwatch.com/companies/sandoz
[2] https://www.uptodate.com/contents/yupelri-revefenacin-drug-information
[3] https://www.drugpatentwatch.com/drug/yupelri
[4] https://www.fiercepharma.com/pharma/mylan-acquires-theravance-biopharmas-respiratory-assets-750m
[5] https://www.drugpatentwatch.com/
[6] https://www.goldcopd.org/wp-content/uploads/2022/03/GOLD-Report-2022-PDF-1.pdf